How much funding has ImmunityBio raised?

ImmunityBio has raised $180.0M in total funding, most recently a Venture Round.

Who are ImmunityBio's investors?

ImmunityBio's investors include Oberland Capital.

When was ImmunityBio founded?

ImmunityBio was founded in 2014.

Where is ImmunityBio headquartered?

ImmunityBio is headquartered in Culver City, California, United States.

What industry is ImmunityBio in?

ImmunityBio operates in Biotech, Healthcare.

How many employees does ImmunityBio have?

ImmunityBio has 201-500 employees.

ImmunityBio

IPO

Immunotherapy by ImmunityBio - Cancer Vaccine Research

Public · Culver City, United States · Founded 2014 · $180.0M raised

Biotech

Healthcare

Headquarters: Culver City, California
Employees: 201–500
Founded: 2014
Business Model: B2B
Website: immunitybio.com

Total Funding: $180.0M
Last Round: $100.0M Venture RoundDec 2025
Rounds: 3
Type: Public

About

ImmunityBio develops next-generation immunotherapies that activate both innate and adaptive immune responses to treat cancer and infectious diseases. Its lead product ANKTIVA received FDA approval in 2024 for non-muscle invasive bladder cancer, and the company applies a 'triangle offense' strategy stimulating NK cells, T cells, macrophages, and dendritic cells to create durable immune responses.

Summary

ImmunityBio is a Biotech company based in Culver City, United States, founded in 2014. It has raised $180.0M in total across 3 rounds, most recently a $100.0M Venture Round round in Dec 2025. Investors include Oberland Capital.

LinkedIn X (Twitter)